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Abstract
Background: The aims of this study were to determine the antimicrobial susceptibility patterns
of urinary isolates from community acquired acute uncomplicated urinary tract infections (uUTI)
and to evaluate which antibiotics were empirically prescribed in the outpatient management of
uUTI.
Methods: Among the patients which were admitted to outpatient clinics of Ankara University
Medical Faculty, Ibni-Sina Hospital during 2005-2006, a total of 429 women between the age of 18
and 65 years old who were clinically diagnosed with uUTI and to whom prescribed empirical
antibiotics were enrolled in this prospective observational study. Patients' demographical data,
urine culture results, resistance rates to antimicrobial agents and prescribed empiric antimicrobial
therapy were analyzed.
Results: Totally 390 (90.9%) patients among all study population were requested for urine culture
by their physicians. 150 (38.5%) of these urine cultures were positive. The most common isolated
uropathogen was Escherichia coli (E. coli) (71.3%). The variations of uropathogens according to age
and menopause status were not significantly different.
The resistance rates of E. coli isolates for ampicillin, ampicillin-sulbactam, amoxicillin-clavulonate,
cefuroxime, ceftriaxone, fluoroquinolones (FQ), co-trimoxazole (TMP-SMX) and gentamicin were
55.1%, 32.7%, 32.7%, 23.4%, 15.9%, 25.2%, 41.1%, 6.1% respectively. FQ were the most common
prescribed antibiotics (77.9%) (P < 0.001), followed by TMP-SMX (10.7%), fosfomycin (9.2%),
nitrofurantoin (2.1%). Treatment durations were statistically longer than the recommended 3-day
course (P < 0.001).
Conclusion:  Empirical use of FQ in uUTI should be discouraged because of increased
antimicrobial resistance rates.
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Background
Community acquired urinary tract infection (UTI) in
women is a prevalent problem in primary care, account-
ing for approximately eight million ambulatory visits
annually in the United States [1]. UTI has several different
clinical presentations [1]. Acute uncomplicated UTI
(uUTI) occurs in otherwise healthy non-pregnant women
with normal genitourinary tract [2]. The current treatment
of uUTI is empirical, based on the limited and predictable
spectrum of etiological microorganisms [3]. However, as
with many community acquired infections, resistance
rates to antimicrobials which are commonly used in uUTI
is increasing and susceptibility of microorganisms shows
significant geographical variations [4-6]. The most impor-
tant driving factor of resistance is overuse of antimicrobi-
als [4-6]. Increasing antimicrobial resistance complicates
uUTI treatment by increasing patient morbidity, costs of
reassessment and re-treatment and use of broader spec-
trum antibiotics. Several studies have demonstrated
increasing antibiotic resistance levels in E. coli causing
community acquired UTI but most in vitro data come
from laboratory based surveys that often do not define the
sex, age, clinical syndrome or other data of interest regard-
ing the patients from whom the urine specimens were col-
lected [7]. And also even in the same country the
susceptibility patterns of the microorganisms exhibit
regional differences [8]. Appropriate knowledge about
local and national antimicrobial resistance trends is the
utmost importance in order to setup evidence based rec-
ommendations in empirical antibiotic treatment of uUTI
[8,9].
We therefore in this prospective observational study
aimed to obtain data on the resistance rates of common
pathogens in 18-65 years old female patients with uUTI
and to determine which empiric antibiotics are prescribed
in relevant settings at our university hospital for the out-
patient management of community acquired uUTI.
Materials and methods
Data collection and Patients
Female patients aged between 18-65 years who attended
to a tertiary care hospital emergency department and out-
patient clinics (Ankara University Medical Faculty Ibni-
Sina Hospital Ankara, Turkey which has 1000 beds and
admits more than 30 000 patients in emergency depart-
ment annually) during the period between 1 March 2005
and 1 September 2006, with symptoms of community
acquired acute uUTI and to whom empiric antibacterial
treatment had prescribed were enrolled in this prospective
observational study.
The symptomatic uUTI described by set of symptoms
involving dysuria, frequency, urgency and suprapubic ten-
derness without the presence of fever. Diagnosis were
made and recorded by the treating physician. Exclusion
criteria were symptoms for > 7 days, signs of pyelonephri-
tis (a body temperature > 38°C orally, flank pain or cos-
tovertebral angle tenderness), three or more episodes of
UTI in the past year, symptoms of UTI in the last three
months, previous upper UTI, other functional and struc-
tural urinary tract abnormalities, indwelling or recent
Foley catheter, previous history of genitourinary system
operation including urinary stones, current pregnancy,
antibiotic use during the previous three months, patients
who were hospitalised for any reason during past three
months, patients with diabetes mellitus and known
immune compromised state.
Patients' demographical data, symptoms, physical exami-
nation results, urinalysis, urine culture results, pathogen
microorganisms and resistance rates to antimicrobials
and prescribed empiric antimicrobial therapy (agent and
duration) were recorded by a trained physician or a nurse.
Laboratory Methods
The urine specimens were taken after instructing the
patient on the midstream technique. Pyuria was detected
either with positive dip-stick test or > 5-10 leucocytes in
the urine centrifuged at 2000 rpm for 5 minutes. Clean-
catch urine samples obtained from patients were inocu-
lated onto 5% blood agar and Eosin-Methylene Blue
(EMB) agar with 0.01 mL calibrated loops by a semi-
quantitative technique. Culture plates were incubated for
18-24 h at 37°C. A threshold of > 105 organisms per mL
of urine defined as a positive culture. The isolated bacteria
were identified by conventional methods and BBL Crystal
Enteric/NF 4.0 identification kits (Becton Dickinson-NY,
USA) were used when needed. The susceptibility of each
isolated pathogen to antibiotics (the fluoroquinolones
(FQ), ampicillin, ampicillin-sulbactam, amoxicillin-cla-
vulonate, co-trimoxazole (TMP-SMX), ceftriaxone, cefuro-
xime, gentamicin) were determined by the Kirby-Bauer
disc diffusion method and by automatic system (Becton
Dickinson). Samples were processed in the University
Hospital Laboratory according to standard procedures
defined by the Clinical and Laboratory Standards Institute
(CLSI, formerly the National Committee for Clinical Lab-
oratory) [10].
The hard paper copies of locally generated reports and
susceptibility results were collected and added to the
patients' records.
Statistical analysis
The data from the study were inserted into MS Excel,
coded than transferred into SPSS 14.0 for Windows for
statistical analysis. Pearson chi-squared test was used to
compare the parameters. Data are presented with 95%Annals of Clinical Microbiology and Antimicrobials 2009, 8:27 http://www.ann-clinmicrob.com/content/8/1/27
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confidence intervals (CI). A P value of < 0.05 was consid-
ered statistically significant.
Ethics
Ethical approval was granted for this study by Ankara Uni-
versity Local Research Ethics Committee (No: 73-1877)
Results
Patient demographics
A total of 429 female patients were diagnosed with uUTI
and received empiric antibiotics included in the study.
78.3% of the patients (336) were enrolled from emer-
gency department, 16.6% of patients (71) from internal
medicine and, 5.1% (22) from urology outpatient clinics.
278 of them (64.8%) were belonged to the age group of
18-50 years. 151 (35.2%) patients were between 50 and
65 years of age. Mean age of the study population was
42.41 (± 14.7). 276 (64.3%) of the patients were premen-
opausal and 153 (35.7%) were postmenopausal.
Isolated uropathogens
Urine culture was ordered for 390 (90.9%; 95% CI 88.1-
93.6%) of the study population by their physicians conse-
quently and 150 (38.5%; 95% CI 33.5-43.4%) of these
cultures were positive for bacterial growth. The remaining
240 specimens (61.5%; 95% CI 56.6-66.4%) were nega-
tive for bacterial growth. 39 (9.1%; 95% CI 6.3-11.8%)
patients received antibiotics without the request of urine
culture. Gram-negative bacteria were found in 115
(76.7%; 95% CI 69.7-83.6%) urines and gram-positive
bacteria in 24 (16%; 95% CI 10-22%), Candida spp. in 11
(7.3%; 95% CI 3.1-11.5%). The distribution of uropatho-
gen groups according to menopausal status were not sig-
nificantly different (Table 1).
The most common isolated uropathogen was E. coli
(71.3%; 95% CI 63.9-78.6%), followed by Staphylococcus
spp. (8%; 95% CI 3.6-12.4%), Candida spp. (7.3%; 95%
CI 3.1-11.5%), Streptococcus  spp. (4.7%; 95% CI 1.2-
8.2%), Klebsiella spp. (4%; 95% CI 0.8-7.2%), Enterococcus
spp. (3.3%; 95% CI 0.2-6.3%), Proteus spp. (1.3%; 95%
CI 0.6-3.2%) were isolated respectively.
Antimicrobial resistance patterns
The antibiotic resistance rates of the isolates are shown in
table 2. The resistance rates of most prevailing microor-
ganism,  E. coli isolates for ampicillin, ampicillin-sul-
bactam, amoxicillin-clavulonate, cefuroxime, ceftriaxone,
FQ, TMP-SMX and gentamicin were 55.1% (95% CI 45.4-
64.7%), 32.7% (95% CI 23.6-41.7%), 32.7% (95% CI
23.6-41.7%), 23.4% (95% CI 15.2-31.6%), 15.9% (95%
CI 8.8-22.9%), 25.2% (95% CI 16.8-33.6%), 41.1% (95%
CI 31.6-50.6%), 6.1% (95% CI 4.4-8.4.7%) respectively.
Resistance to TMP-SMX (41.1%; 95% CI 31.6-50.6%) was
found to be higher than FQ resistance (25.2% 95% CI
16.8-33.6%). FQ+TMP-SMX dual resistance was 17.8%
(95% CI 10.4-25.2%) among the E. coli isolates. Although
there was a tendency in increase of resistance rates to all
beta-lactam antibiotics in patients older than fifty years of
age, only cefuroxime resistance in E. coli isolates according
the age group of patients was statistically significant
(17.3% versus 37.5%; P < 0.05), (Table 3).
Prescribed antimicrobials and treatment durations
For 429 patients with uUTI, FQ were the most common
empirically prescribed antibiotics (77.9%; 95% CI 73.9-
82.1%) by the physicians compared to TMP-SMX (10.7%;
95% CI 7.7-13.7%), fosfomycin (9.2%; 95% CI 6.4-12%),
nitrofurantoin (2.1%; 95% CI 0.7-3.5%) (P < 0.001). The
first choice among FQ was ciprofloxacin (82.7%; 95% CI
78.6-86.8%) followed by ofloxacin (7.6%; 95% CI 4.7-
10.5%) levofloxacin (7.3%; 95% CI 4.5-10.1) and moxi-
floxacin (2.4%%; 95% CI 0.7-4.1%), (Table 4). Treatment
durations were statistically longer than the recommended
3-day course; 1-3 day (9.4%; 95% CI 6.6-12.2%), 5 days
(7.5%; 95% CI 4.9-10%), 7 days (70.4%; 95% CI 65.9-
74.8%), > 7 days (12.7%; 95% CI 9.5-15.9%) (P < 0.001),
(Figure 1). Prescription rates of the different classes of
drugs and duration of treatment were not statistically sig-
nificant between age groups (P = 0.469 and P = 0.615
respectively).
Discussion
This study shows the distribution of microbial species iso-
lated from patients with uUTI and their resistance rates to
antimicrobial agents at a university hospital in Turkey.
Table 1: The distribution of microorganisms according to menopausal status
Microorganism Premenopause n (%) Postmenopause n (%) P value
Gram (-)bacteria 81 (80.2%) 34 (69.4%) 0,142
Gram (+)bacteria 14 (13.9%) 10 (20.4%) 0.305
Candida spp. 6 (5.9%) 5 (10.2%) 0.348
Total 101 (% 100) 49 (% 100)Annals of Clinical Microbiology and Antimicrobials 2009, 8:27 http://www.ann-clinmicrob.com/content/8/1/27
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As it has previously been reported, we found the majority
of patients with uUTI were under 50 years of age and the
predominant bacterium was E. coli [11]. The uropatho-
gens isolated in this patient population were similar to
those in other comparable studies [12,13]. It was reported
that in postmenopausal women owing to the loss of oes-
trogen and consequent changes in vaginal flora, the etio-
logical agents in uUTI can be different from
premenopausal patients [14-16]. Our data have not
revealed such a difference between these two groups of
patients.
Main international guidelines recommend empirical ther-
apy in uUTI [17,18]. The efficacy of such empirical ther-
apy depends on periodic assessment of antimicrobial
resistance profiles. Although the spectrum of bacteria iso-
lated from patients with uUTI worldwide has remained
largely unchanged in which E. coli is the most prevalent
microorganism, there have been significant changes in the
resistance patterns of uropathogens over the past few dec-
ades and antibiotic resistance has become a major prob-
lem in uUTI [13]. Increasing antimicrobial resistance has
been documented all over the world [11,19,20]. Resist-
ance rates among strains of E. coli isolated from women
with uUTI averages 30% for both sulphonamides and
Table 2: Isolated bacteria and their resistance rates to antimicrobial agents in 139* urine samples
Bacterium % 
resistance
(n, %)
Ampicillin Ampicillin-
Sulbactam
Cefuroxime Ceftriaxone Amoxicillin-
clavulonate
Fluoroquinol
ones
Gentamicin TMP-SMX§
E. coli
% resistance
(107, 71.3%)
55.1 32.7 23.4 15.9 32.7 25.2 6.1 41.1
Staphylococcus 
spp.
% resistance 
(12, 8%)
_** 41.7 41.7 _** 41.7 41.7 41.7 33.3
Streptococcus 
spp.
% resistance 
(7, 4.7%)
00 0 0 0 0 _ * * _ * *
Klebsiella spp.
% resistance 
(6, 4%)
100 16.7 16,7 0 16,7 0 16.7 16,7
Proteus spp.
% resistance 
(2, 1.3%)
00 0 0 0 0 0 0
Enterococcus 
spp.
% resistance 
(5, 3.3%)
0 _** _** _** _** 20 40 _**
* Candida isolates were not included; n = number of isolates; ** = not determined; § = co-trimoxazole
Table 3: Resistance rates of E. coli strains according the age 
groups
Antimicrobial Agent Age < 50 Age  50 P value
Ampicillin 54.7% 56.3% 0.880
Ampicillin-sulbactam 29.3% 40.6% 0.254
Amoxicillin-clavulonate 29.3% 40.6% 0.254
Cefuroxime 17.3% 37.5% 0.024*
Ceftriaxone 13.3% 21.9% 0.268
Fluoroquinolone 22.7% 31.3% 0.349
Gentamicin 5.8% 6.3% 0.585
TMP-SMX** 46.7% 28.1% 0.074
TMP-SMX+FQ*** 18.7% 15.6% 0.706
* = P < 0.05; ** = co-trimoxazole; *** = co-trimoxazole, 
fluoroquinolone dual resistance
Antimicrobial treatment durations (%) * P < 0.001 Figure 1
Antimicrobial treatment durations (%) * P < 0.001.
* P < 0.001 Annals of Clinical Microbiology and Antimicrobials 2009, 8:27 http://www.ann-clinmicrob.com/content/8/1/27
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ampicillin, varying from 17% to 54% in different coun-
tries [11]. Trimethoprim resistance ranges from 11% in
Scandinavian countries to 34% in Spain and Portugal. FQ
resistance was not found in Scandinavian countries but
reaches 20% in southern Europe [11]. Recently Gober-
nado et al. showed reduced susceptibility of E. coli strains
isolated from patients with uUTI to TMP-SMX (26%) and
to FQ (16%) in Spain where antimicrobials can be used
without restriction [8]. The variability amongst different
centres confirms the need for local resistance prevalence
data to be available to the practitioner who treats UTI,
especially where empirical therapy is being used for uri-
nary infections.
Our study clearly shows that there is a significant increase
in TMP-SMX and FQ resistance among E. coli isolates from
patients with uUTI in our region which makes the empir-
ical treatment of uUTI a great challenge. This observation
is in accordance with recent studies conducted in Spain
and Europe [8,11]. Arslan et al. reported 36% resistance to
TMP-SMX and 17% resistance rates to FQ among 288 E.
coli isolates from patients with uUTI in Turkey [21]. Also
Ozyurt et al. have found 34% resistance to TMP-SMX and
18% resistance to FQ among community-acquired
uropathogen E. coli isolates from Istanbul region [22]. The
reported rates of resistance among uropathogens may vary
depending on whether study sample consist of primarily
of outpatients with uUTI or patients with complicated
UTI.
Influence of age has previously been shown to have an
impact on resistance rates in UTI [20,21,23,24]. Although
our study population was younger than comparable stud-
ies, E. coli isolates of this study were also more likely to be
resistant to ampicillin, ampicillin-sulbactam, amoxicillin-
clavulonate, ceftriaxone, gentamicin, and FQ in the
patients over fifty years of age. Cefuroxime resistance is
the only statistically significant one.
In several studies it has been shown that the prescribing
habits of the physicians are the driving factor for the anti-
biotic resistance [25-27]. Goettsche et al. reported that the
resistance against FQ is strongly associated with a high
number of prescriptions for this group of antibiotics [25].
Because of aforementioned reasons pharmacological sur-
veillance is an essential part of antimicrobial agent resist-
ance studies. Although the association between
antimicrobial agent utilisation and resistance in hospital
services is well known, there is a lack of information for
the same issue in community acquired infections [28-30].
There are relatively few studies published on variations in
treatment for uUTI. McEwen et al. found that 37% of phy-
sicians actually prescribe TMP-SMX, closely followed by
FQ (32%) and average duration of antibiotic therapy was
8.6 days in the United States [31]. Kahan NR et al. revealed
that FQ were the most frequently prescribed drugs
(25.57%) in Israel [32]. In our study we found that
although not recommended as first line antibiotic, FQ
were the most frequent empirically prescribed drugs in
our hospital settings for uUTI. In the FQ group, cipro-
floxacin was the most commonly prescribed drug and the
average duration of the therapy was longer than the rec-
ommended 3 days. The prescribed antimicrobial agent
and duration of the treatment were not different between
age groups.
To our knowledge this is the first study in Turkey which
directly evaluates the prescription behaviour of treating
physicians on a medical condition. The data have not
been collected from a drug surveillance database or from
medical records retrospectively without knowledge of
patient's clinical situation. The results are based on the
actual physician habits, so it does give an accurate descrip-
tion of which antibiotics are prescribed and the duration
of therapy. Since uUTI is relatively common, widespread
inappropriate prescribing increases resistance among
uropathogens. Our resistance rates to FQ among E. coli
strains were found to be much higher than other Euro-
pean studies. This may be due to high use of FQ, since it
is considered the antimicrobial group of choice in UTI.
Inappropriate antibiotic prescribing for UTI was docu-
mented in 47.3% of patients in a study from Turkey [33].
In addition to increasing risk of resistance; current pre-
scribing patterns in our hospital increase the medical
costs. In this study we also found that newer FQ like moxi-
floxacin and levofloxacin were also prescribed for the
treatment of uUTI. It is known that among susceptible iso-
lates, the more expensive broad-spectrum FQ are not
more effective than the cheaper alternatives [1,12].
Limitations
Although it is local, we believe that in this observational
prospective study we reached our goal in terms of obtain-
Table 4: Empirically prescribed antimicrobial agents
Antimicrobial Agent n %
Fluoroquinolone 334 77.9%
Ciprofloxacin 277 82.7%
Ofloxacin 25 7.6%
Levofloxacin 24 7.3%
Moxifloxacin 8 2.4%
TMP-SMX*4 6 1 0 . 7 %
Fosfomycin 40 9.2%
Nitrofurantoin 9 2.1%
Total 429 100%
* = co-trimoxazoleAnnals of Clinical Microbiology and Antimicrobials 2009, 8:27 http://www.ann-clinmicrob.com/content/8/1/27
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ing precise scientific data dealing with the resistance rates
of uropathogens in a university hospital serving to the
central Anatolia region. At the same time we had an
opportunity to evaluate the actual prescribing habits of
our physicians in a medical condition which is most of
the times improperly treated.
We did not have a chance to evaluate the resistance pat-
terns of E. coli isolates to the other alternative antimicro-
bials such as nitrofurantoin and fosfomycin due to the
lack of antimicrobial discs in our hospital laboratory.
Further studies with larger number of isolates from each
individual geographical region are needed to confirm our
results. However clinicians should be aware of regional
resistance rates and it should be taken into consideration
before initiating empirical antimicrobial therapy for
uUTI.
Conclusion
FQ should be used with consideration since the resistance
to FQ is in increase; rather it ought to be prescribed for
treatment of serious infections like connective tissue
infections, respiratory tract infections and upper UTI. If
conditions allowing use of nonfluoroquinolone drugs for
the treatment of uUTI should be encouraged when TMP-
SMX is not an option. Since uUTI is relatively easy to cure
with limited morbidity, agents like nitrofurantoin and
fosfomycin should be used instead of FQ.
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